Acumen Pharmaceuticals IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Acumen Pharmaceuticals | ABOS - NASDAQ |
$14.00-$16.00 | $16.00 | $25.07 | 10 million | 7/1/2021 |
| BofA Securities, Credit Suisse, Stifel | ||||||
Co-Manager(s): UBS Investment Bank | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-06-09 Terms Added 2021-06-24 | ||||||
Acumen Pharmaceuticals Quote & Chart - Click for current quote - ABOS
IPO Boutique aggregates information on public companies and private companies, such as "ABOS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Acumen Pharmaceuticals (adapted from Acumen Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer’s disease, or AD.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer’s disease, or AD.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ABOS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.